Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists
Open accessThe DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Abstract
TrkB is a tyrosine kinase receptor that is activated upon binding to brain-derived neurotrophic factor (BDNF). To date, the search for low-molecular-weight molecules mimicking BDNF’s action has been unsuccessful. Several molecules exerting antidepressive effects in vivo, such as 7,8-DHF, have been suggested to be TrkB agonists. However, more recent publications question this hypothesis. In this study, we developed a set of experimental procedures including the evaluation of direct interactions, dimerization, downstream signaling, and cytoprotection in parallel with physicochemical and ADME methods to verify the pharmacology of 7,8-DHF and other potential reference compounds, and perform screening for novel TrkB agonists. 7,8 DHF bound to TrkB with Kd = 1.3 μM; however, we were not able to observe any other activity against the TrkB receptor in SN56 T48 and differentiated SH-SY5Y cell lines. Moreover, the pharmacokinetic and pharmacodynamic effects of 7,8-DHF at doses of 1 and 50 mg/kg were examined in mice after i.v and oral administration, respectively. The poor pharmacokinetic properties and lack of observed activation of TrkB-dependent signaling in the brain confirmed that 7,8-DHF is not a relevant tool for studying TrkB activation in vivo. The binding profile for 133 molecular targets revealed a significant lack of selectivity of 7,8-DHF, suggesting a distinct functional profile independent of interaction with TrkB. Additionally, a compound library was screened in search of novel low-molecular-weight orthosteric TrkB agonists; however, we were not able to identify reliable drug candidates. Our results suggest that published reference compounds including 7,8-DHF do not activate TrkB, consistent with canonical dogma, which indicates that the reported pharmacological activity of these compounds should be interpreted carefully in a broad functional context.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many scaffolds suffer rapid clearance, metabolic instability, and uneven brain exposure [62,131,132].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several proposed low molecular weight TrkB agonists have raised reproducibility and target specificity concerns, and central exposure remains difficult to optimize across scaffolds [131,132].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [131]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotrophins: Roles in Neuronal Development and Function
Huang, E. J., & Reichardt, L. F. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.677 · Cited by 4,394 · cited 1×
“At the cellular level, BDNF acts as a key regulator of neurite outgrowth, synaptic plasticity, and long-term potentiation in the central nervous system [1,2].”
BackgroundNeurotrophin-regulated signalling pathways
Reichardt, L. F. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2006.1894 · Cited by 2,195 · cited 2×
“The binding affinity differs between these molecules, and BDNF and NT4 interact much stronger with TrkB than NT3 [31].”
BackgroundNeurotrophin regulation of neural circuit development and function
Park, H., & Poo, M.-M. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3379 · Cited by 2,060 · cited 1×
“At the cellular level, BDNF acts as a key regulator of neurite outgrowth, synaptic plasticity, and long-term potentiation in the central nervous system [1,2].”
BackgroundBDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra
Hyman, C., Hofer, M., Barde, Y.-A., Juhasz, M., Yancopoulos, G. D., Squinto, S. P., & Lindsay, R. M. (1991) · Nature · doi:10.1038/350230a0 · Cited by 1,494 · cited 1×
“BDNF has antiapoptotic and neurotrophic properties affecting the viability and physiological condition of neurons [3,4].”
BackgroundDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 2×
“These may include side effects such as insomnia, sleepiness, and weight gain [10], and limited efficacy in drug-resistant forms of the disease [11].”
BackgroundConsiderations for the use of SH-SY5Y neuroblastoma cells in neurobiology
Kovalevich, J., & Langford, D. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-640-5_2 · Cited by 1,005 · cited 1×
“The SH-SY5Y cell line differentiated by retinoic acid (RA) is a widely used neuron-like model in neurobiological research [27].”
Colucci-D’Amato, L., Speranza, L., & Volpicelli, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207777 · Cited by 991 · cited 2×
“The cytoprotective effect of BDNF has been demonstrated in many in vitro and in vivo models [28].”
BackgroundBDNF - a key transducer of antidepressant effects
Björkholm, C., & Monteggia, L. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.034 · Cited by 958 · cited 1×
“Furthermore, BDNF appears to be a key transducer in mediating the therapeutic effects of known antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and ketamine, by inducing changes in neuroplasticity [9].”
BackgroundThe GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934 · cited 1×
“The interaction of the GABAA receptor was clinically proved to produce anxiolytic and antidepressant effects via reversing deficits in monoamine transmission in GABAergic machinery [42].”
BackgroundPharmacology of Adenosine Receptors: The State of the Art
Borea, P. A., Gessi, S., Merighi, S., Vincenzi, F., & Varani, K. (2018) · Physiological Reviews · doi:10.1152/physrev.00049.2017 · Cited by 783 · cited 1×
“A1A receptors reduce excitatory transmission by the regulation of potassium homeostasis, which leads to the inhibition of glutamate secretion in neuronal cells, whereas the A2A receptor modulates the sensitivity of the dopamine D2 receptor, typically in striatal neurons, which affects motoric functions [44].”
Background
Cited by
TrkB/BDNF signaling pathway and its small molecular agonists in CNS injury
Wang, Y., Liang, J., Xu, B., Yang, J., Wu, Z., & Cheng, L. (2024) · Life Sciences · doi:10.1016/j.lfs.2023.122282 · Cited by 152
TrkB Truncated Isoform Receptors as Transducers and Determinants of BDNF Functions
Tessarollo, L., & Yanpallewar, S. U. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.847572 · Cited by 89
Róg, T., Girych, M., & Bunker, A. (2021) · Pharmaceuticals · doi:10.3390/ph14101062 · Cited by 70
Unlocking Alzheimer’s Disease: The Role of BDNF Signaling in Neuropathology and Treatment
Alqahtani, S. M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Alexiou, A. T., Papadakis, M., Hemeda, L. R., Faheem, S. A., & Batiha, G. E. (2025) · NeuroMolecular Medicine · doi:10.1007/s12017-025-08857-x · Cited by 59
“In addition, allosteric interaction with TrkB offers new opportunities, and a shift toward the crossed transmembrane domain of the TrkB receptor as a target for novel agonist pharmacophores should be considered in future development engaging the BDNF/TrkB signaling pathway (Pankiewicz et al., 2021).”
Neurotrophin-targeted therapeutics: A gateway to cognition and more?
Nordvall, G., Forsell, P., & Sandin, J. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.07.003 · Cited by 48
Metadata
- Authors
- Pankiewicz, P., Szybiński, M., Kisielewska, K., Gołębiowski, F., Krzemiński, P., Rutkowska-Włodarczyk, I., Moszczyński-Pętkowski, R., Gurba-Bryśkiewicz, L., Delis, M., Mulewski, K., Smuga, D., Dominowski, J., Janusz, A., Górka, M., Abramski, K., Napiórkowska, A., Nowotny, M., Dubiel, K., Kalita, K., Wieczorek, M., Pieczykolan, J., & Matłoka, M.
- Affiliations
- Medical University of Warsaw (PL)
- Celon Pharma (Poland) (PL)
- Structural Biology Center, International Institute of Molecular and Cell Biology, 02-109 Warsaw, Poland
- International Institute of Molecular and Cell Biology (PL)
- Instytut Biologii Doświadczalnej im. Marcelego Nenckiego (PL)
- Corresponding author
- Matłoka, Mikołaj
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2021-07-21
- Volume
- 14
- Issue
- 8
- Pages
- 704
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC8398766
- OpenAlex
- W3186036424
- Cited by
- 42
- References
- 54
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 10 · 2023: 9 · 2022: 5 · 2021: 2
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Narodowe Centrum Badań i Rozwoju (POIR.01.02.00-00-0020/17-00)
- Ministerstwo Nauki i Szkolnictwa Wyższego (Doktorat Wdrożeniowy 50//DW/2017/01/1)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Keywords
- TrkB receptor, brain-derived neurotrophic factor, orthosteric agonists, receptor activation, pharmacokinetics, pharmacodynamics, receptor dimerization, downstream signaling, compound library screening, target selectivity, receptor tyrosine kinase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists. https://app.cochat.ai/papers/10.3390/ph14080704
- The paper
- Pankiewicz, P., Szybiński, M., Kisielewska, K., Gołębiowski, F., Krzemiński, P., Rutkowska-Włodarczyk, I., Moszczyński-Pętkowski, R., Gurba-Bryśkiewicz, L., Delis, M., Mulewski, K., Smuga, D., Dominowski, J., Janusz, A., Górka, M., Abramski, K., Napiórkowska, A., Nowotny, M., Dubiel, K., Kalita, K., . . . Matłoka, M. (2021). Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists. Pharmaceuticals. https://doi.org/10.3390/ph14080704
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.